• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口服β-内酰胺类药物法罗培南对美国近期分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的活性。

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

作者信息

Critchley Ian A, Karlowsky James A, Draghi Deborah C, Jones Mark E, Thornsberry Clyde, Murfitt Kate, Sahm Daniel F

机构信息

Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171, USA.

出版信息

Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.

DOI:10.1128/AAC.46.2.550-555.2002
PMID:11796376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC127058/
Abstract

The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725 Streptococcus pneumoniae isolates, 2,614 Haemophilus influenzae isolates, and 1,193 Moraxella catarrhalis isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 microg/ml for penicillin-susceptible, -intermediate, and -resistant S. pneumoniae strains, respectively; 0.5 and 1 microg/ml for beta-lactamase-positive and -negative H. influenzae strains, respectively; and 0.12 and 0.5 microg/ml for beta-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.

摘要

1999年期间，从美国273家实验室收集了4725株肺炎链球菌、2614株流感嗜血杆菌和1193株卡他莫拉菌，测定了法罗培南和其他抗菌药物的体外活性。对于青霉素敏感、中介和耐药的肺炎链球菌菌株，抑制90%菌株的法罗培南最低抑菌浓度（MIC）分别为0.008、0.25和1微克/毫升；对于β-内酰胺酶阳性和阴性的流感嗜血杆菌菌株，MIC分别为0.5和1微克/毫升；对于β-内酰胺酶阴性和阳性的卡他莫拉菌菌株，MIC分别为0.12和0.5微克/毫升。法罗培南有望成为社区获得性呼吸道感染的口服治疗药物。

相似文献

1
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.口服β-内酰胺类药物法罗培南对美国近期分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的活性。
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.
2
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.2005 - 2006年美国法罗培南监测研究中确定的社区获得性呼吸道病原体的国家和地区抗菌药物耐药性评估。
Antimicrob Agents Chemother. 2007 Dec;51(12):4382-9. doi: 10.1128/AAC.00971-07. Epub 2007 Oct 1.
3
Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.肺炎链球菌、流感嗜血杆菌和卡他莫拉菌分离株对26种抗菌药物的敏感性调查：一项美国前瞻性研究。
Antimicrob Agents Chemother. 1999 Nov;43(11):2612-23. doi: 10.1128/AAC.43.11.2612.
4
The in vitro effects of faropenem on lower respiratory tract pathogens isolated in the United Kingdom.法罗培南对在英国分离出的下呼吸道病原体的体外作用。
Int J Antimicrob Agents. 2003 Jun;21(6):581-4. doi: 10.1016/s0924-8579(03)00049-9.
5
[Serotype distribution and drug resistance of , and isolated from nasopharynx of Uygur children].[从维吾尔族儿童鼻咽部分离出的、和的血清型分布及耐药性]
Zhonghua Er Ke Za Zhi. 2018 Apr 2;56(4):279-283. doi: 10.3760/cma.j.issn.0578-1310.2018.04.008.
6
Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.美国流感嗜血杆菌、卡他莫拉菌和肺炎链球菌呼吸道分离株中的抗菌药物耐药性
Antimicrob Agents Chemother. 1990 Nov;34(11):2075-80. doi: 10.1128/AAC.34.11.2075.
7
Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.抗生素耐药时代口服β-内酰胺类抗菌药物对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌呼吸道分离株的活性
Otolaryngol Head Neck Surg. 2002 Dec;127(6 Suppl):S17-23. doi: 10.1067/mhn.2002.130029.
8
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.美国2000 - 2001年和2001 - 2002年TRUST研究中儿童肺炎链球菌、流感嗜血杆菌和卡他莫拉菌临床分离株对左氧氟沙星的敏感性
Antimicrob Agents Chemother. 2003 Jun;47(6):1790-7. doi: 10.1128/AAC.47.6.1790-1797.2003.
9
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.1996 - 1997年呼吸道疾病流行季节美国肺炎链球菌、流感嗜血杆菌和卡他莫拉菌耐药性监测。实验室研究小组。
Diagn Microbiol Infect Dis. 1997 Dec;29(4):249-57. doi: 10.1016/s0732-8893(97)00195-8.
10
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.流感嗜血杆菌和卡他莫拉菌呼吸道分离株中的抗菌药物耐药性：1997年至2002年加拿大呼吸道病原体敏感性研究结果
Antimicrob Agents Chemother. 2003 Jun;47(6):1875-81. doi: 10.1128/AAC.47.6.1875-1881.2003.

引用本文的文献

1
Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016.2016 年美国侵袭性流感嗜血杆菌的抗菌药物敏感性调查。
Microbiol Spectr. 2022 Jun 29;10(3):e0257921. doi: 10.1128/spectrum.02579-21. Epub 2022 May 10.
2
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.2005 - 2006年美国法罗培南监测研究中确定的社区获得性呼吸道病原体的国家和地区抗菌药物耐药性评估。
Antimicrob Agents Chemother. 2007 Dec;51(12):4382-9. doi: 10.1128/AAC.00971-07. Epub 2007 Oct 1.
3
Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel.法罗培南对来自哥斯达黎加和以色列急性中耳炎患儿中耳积液病原体的活性。
Antimicrob Agents Chemother. 2007 Jun;51(6):2230-5. doi: 10.1128/AAC.00049-07. Epub 2007 Mar 26.
4
Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs.阿莫西林最低抑菌浓度高于青霉素最低抑菌浓度的肺炎链球菌分离株中青霉素结合蛋白1A、2X和2B的改变。
Antimicrob Agents Chemother. 2004 Oct;48(10):4020-2. doi: 10.1128/AAC.48.10.4020-4022.2004.
5
Longitudinal assessment of antipneumococcal susceptibility in the United States.美国抗肺炎球菌药敏性的纵向评估。
Antimicrob Agents Chemother. 2002 Aug;46(8):2651-5. doi: 10.1128/AAC.46.8.2651-2655.2002.

本文引用的文献

1
In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.新型口服碳青霉烯类药物L-084对呼吸道感染病原菌的体内外抗菌活性
Antimicrob Agents Chemother. 2001 Jan;45(1):203-7. doi: 10.1128/AAC.45.1.203-207.2001.
2
In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins.新型口服碳青霉烯类化合物DZ-2640的活性形式DU-6681a与R-95867、法罗培南及口服头孢菌素类药物的体外活性比较
J Antimicrob Chemother. 2000 Jul;46(1):101-8. doi: 10.1093/jac/46.1.101.
3
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.1997 - 1998年美国分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的耐药性监测
J Antimicrob Chemother. 1999 Dec;44(6):749-59. doi: 10.1093/jac/44.6.749.
4
Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial surveillance program 1997. SENTRY Participants Group.欧洲社区获得性肺炎分离株中的抗菌药物耐药性：1997年SENTRY抗菌药物监测计划的初步结果。SENTRY参与者小组
Int J Infect Dis. 1999 Spring;3(3):153-6. doi: 10.1016/s1201-9712(99)90037-1.
5
Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996.细菌性呼吸道病原体的抗菌药物敏感性趋势——1992 - 1996年亚历山大项目的研究结果
J Chemother. 1999 Feb;11 Suppl 1:5-21. doi: 10.1179/joc.1999.11.Supplement-2.5.
6
Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.1994年和1995年美国流感嗜血杆菌临床分离株的抗生素耐药性以及对阿莫西林-克拉维酸耐药的β-内酰胺酶阳性菌株的检测：一项全国多中心监测研究的结果
Antimicrob Agents Chemother. 1997 Feb;41(2):292-7. doi: 10.1128/AAC.41.2.292.
7
Meropenem: a microbiological overview.美罗培南：微生物学概述。
J Antimicrob Chemother. 1995 Jul;36 Suppl A:1-17. doi: 10.1093/jac/36.suppl_a.1.
8
Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.WY-49605与阿莫西林、阿莫西林-克拉维酸、亚胺培南、环丙沙星、头孢克洛、头孢泊肟、头孢呋辛、克林霉素及甲硝唑对384株厌氧菌的活性比较。
Antimicrob Agents Chemother. 1994 Nov;38(11):2599-604. doi: 10.1128/AAC.38.11.2599.
9
In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.新型口服青霉烯类抗生素SY5555的体外抗菌活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1994 Sep;38(9):1974-9. doi: 10.1128/AAC.38.9.1974.
10
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.185株对青霉素敏感和耐药的肺炎球菌对新型口服青霉烯类药物WY-49605（SUN/SY 5555）的体外药敏情况，并与它们对青霉素G、阿莫西林、阿莫西林-克拉维酸、头孢克肟、头孢克洛、头孢泊肟、头孢呋辛和头孢地尼的药敏情况进行比较。
Antimicrob Agents Chemother. 1994 Dec;38(12):2902-4. doi: 10.1128/AAC.38.12.2902.